Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Kidney transplant study compares immune effects of two common drugs

NCT ID NCT02894606

Knowledge-focused Sponsor: University Hospital, Brest Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 49 kidney transplant patients to see how two different induction therapies—thymoglobulin and basiliximab—affect B cells, a type of immune cell. Researchers compared the B cell profiles between the two groups and with data from patients who had chronic antibody-mediated rejection. The goal was to better understand how these drugs influence the immune system after transplant.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Thymoglobulin and basiliximab (induction therapies given before kidney transplant to prevent rejection)
What this could lead to
If successful, this could help doctors choose the best induction therapy for kidney transplant patients and reduce the risk of chronic rejection.
What could go wrong
This is a small, observational study that does not test a new treatment. It only looks at immune cell changes, so it may not lead to direct improvements in patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

49 people

The number who actually took part.

Started

Feb 2015

Finished

May 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

kidney graft recipients from two French renal transplantation centers

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \>18 years old * Recipient of a renal allograft * Patient receiving either basiliximab or thymoglobulin as in induction therapy for renal transplant * Patient presenting a low immunologic risk * Patient not opposed to his (her) study participation Exclusion Criteria: * Patient participating in a clinical trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End-stage renal disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Renal transplant

Contacts and locations

Locations

  • CHU Brest

    Brest, 29200, France

  • Tours University Hospital

    Tours, 37000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.